Core Points - The National Healthcare Security Administration (NHSA) has announced the results of the expert review phase for the 2025 National Basic Medical Insurance Directory and Commercial Insurance Innovative Drug Directory adjustments [1][2] - Companies can check the review results through the NHSA service platform and must submit required documents by specified deadlines [1][2] Group 1 - Companies can log into the NHSA service platform to query the expert review results for the 2025 National Basic Medical Insurance Directory and Commercial Insurance Innovative Drug Directory adjustments [1] - The expert review results include categories such as "proposed simple renewal," "proposed renegotiation renewal," "proposed negotiation addition," "proposed competitive addition," and "proposed price negotiation" [1][2] - Companies must download the corresponding confirmation letter template and submit it by September 23, 2025, along with the original documents sent to the NHSA [1][2] Group 2 - For drugs confirmed to participate in negotiations, competitive bidding, and price negotiations, companies must download the relevant submission material templates and ensure the completeness and authenticity of the submitted data [2] - The review results indicating "proposed negotiation addition," "proposed competitive addition," and "proposed price negotiation" do not guarantee inclusion in the National Basic Medical Insurance Directory or Commercial Insurance Innovative Drug Directory [2] - A communication meeting for companies involved in negotiations and bidding will be held in Beijing, with details to be announced later [2]
2025年国家基本医保目录及商保创新药目录调整通过形式审查的申报药品专家评审阶段性结果查询发布
Di Yi Cai Jing·2025-09-20 04:30